Professional
Added to YB: 2025-06-05
Pitch date: 2025-03-31
MRK [neutral]
Merck & Co., Inc.
+39.54%
current return
Author Info
No bio for this author
Company Info
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
Market Cap
$298.8B
Pitch Price
$86.60
Price Target
N/A
Dividend
2.81%
EV/EBITDA
11.34
P/E
16.60
EV/Sales
5.15
Sector
Pharmaceuticals
Category
value
Artisan Partners Value Fund Portfolio Holding: Merck & Co., Inc.
MRK (holding update): Down 9% on weak China Gardasil demand & shipment pause until mid-2025. Q4 beat but investors focused on Keytruda patent cliff (50% of sales) in 2028. Cheap at 10x P/E with 60+ clinical programs getting little credit. Strong balance sheet & FCF enable M&A, dividends & buybacks.
Read full article (1 min)